Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:KERX
- CUSIP: 49251510
- Web: www.keryx.com
Capitalization:- Market Cap: $765.77 million
- Outstanding Shares: 108,467,000
Average Prices:- 50 Day Moving Avg: $7.08
- 200 Day Moving Avg: $6.08
- 52 Week Range: $4.03 - $8.38
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -30.70
- P/E Growth: -0.09
Sales & Book Value:- Annual Revenue: $36.98 million
- Price / Sales: 20.71
- Book Value: ($0.21) per share
- Price / Book: -33.62
Profitability:- EBIDTA: ($121,500,000.00)
- Net Margins: -387.12%
- Return on Equity: -1,122.28%
- Return on Assets: -88.17%
Debt:- Debt-to-Equity Ratio: -5.55%
- Current Ratio: 5.39%
- Quick Ratio: 4.82%
Misc:- Average Volume: 1.52 million shs.
- Beta: 5.26
- Short Ratio: 11.8
Frequently Asked Questions for Keryx Biopharmaceuticals (NASDAQ:KERX)
What is Keryx Biopharmaceuticals' stock symbol?
Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."
How were Keryx Biopharmaceuticals' earnings last quarter?
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced its quarterly earnings data on Thursday, July, 27th. The company reported ($0.77) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.60. The company had revenue of $15.10 million for the quarter, compared to analysts' expectations of $14.51 million. Keryx Biopharmaceuticals had a negative net margin of 387.12% and a negative return on equity of 1,122.28%. The business's revenue for the quarter was up 62.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.42) earnings per share. View Keryx Biopharmaceuticals' Earnings History.
Where is Keryx Biopharmaceuticals' stock going? Where will Keryx Biopharmaceuticals' stock price be in 2017?
10 equities research analysts have issued 12 month target prices for Keryx Biopharmaceuticals' stock. Their forecasts range from $7.00 to $10.00. On average, they anticipate Keryx Biopharmaceuticals' share price to reach $8.33 in the next twelve months. View Analyst Ratings for Keryx Biopharmaceuticals.
What are analysts saying about Keryx Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:
- 1. Maxim Group analysts commented, "Summary Conclusion: We see little to no effect from this news on the commercial outlook for Auryxia." (7/20/2017)
- 2. According to Zacks Investment Research, "Keryx intends to focus on the growth of Auryxia in the U.S. dialysis market. Meanwhile, the company’s label expansion efforts on Auryxia in the iron-deficiency anemia (IDA) indication seem to be encouraging, given that the IDA market holds great potential. The FDA accepted for review the supplemental New Drug Application (sNDA) for Auryxia tablets for the same indication and has set the Prescription Drug User Fee Act (PDUFA) target action date as Nov 6, 2017. A potential approval should boost sales.. Moreover, shares of the company have outperformed the Medical-Biomed/Genetic Market in year to date. However, considering that the company is heavily dependent on Auryxia for growth, any further interruption in the supply of Auryxia will hamper its growth trajectory, going forward." (7/17/2017)
- 3. JMP Securities analysts commented, "Hogan Reward"The expert cited Keryx Biopharmaceuticals (NASDAQ: KERX)'s sulodexide as an example of a development-stage asset that failed such a confirmation in another kidney disease called diabetic nephropathy.The DUET study has rolled over onto the open-label portion, although the active control irbesartan will not be carried forward, thus it may be difficult to detect a treatment benefit."We believe that we will need to wait until year end to determine if the company can convince the FDA that an accelerated approval pathway can meet the agency's needs," analyst Liisa Bayko wrote in a note."Our sensitivity analysis shows that the stock currently reflects the sentiment that accelerated approval is unlikely," (9/8/2016)
Who are some of Keryx Biopharmaceuticals' key competitors?
Some companies that are related to Keryx Biopharmaceuticals include Array BioPharma (ARRY), Acceleron Pharma (XLRN), Dermira (DERM), Clinigen Group PLC (CLIN), Xencor (XNCR), Amarin Corporation PLC (AMRN), Insmed (INSM), NeuroDerm (NDRM), Acorda Therapeutics (ACOR), Omeros Corporation (OMER), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), Aclaris Therapeutics (ACRS), Retrophin (RTRX), Flexion Therapeutics (FLXN) and ZIOPHARM Oncology (ZIOP).
Who are Keryx Biopharmaceuticals' key executives?
Keryx Biopharmaceuticals' management team includes the folowing people:
- Gregory Paul Madison, Chief Executive Officer, Director
- Scott A. Holmes, Chief Financial Officer, Treasurer
- Christine A. Carberry, Chief Operating Officer
- Douglas M. Jermasek, Vice President of Marketing and Strategy
- Brian R. Adams, General Counsel, Secretary
- Lora Pike, Senior Director
- John F. Neylan, Chief Medical Officer
- John P. Butler, Independent Director
- Kevin J. Cameron, Independent Director
- Steven C. Gilman Ph.D., Independent Director
Who owns Keryx Biopharmaceuticals stock?
Keryx Biopharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.08%), Janney Montgomery Scott LLC (0.07%), Bank of Montreal Can (0.06%), Northeast Financial Consultants Inc (0.04%), Baldwin Brothers Inc. MA (0.04%) and Creative Planning (0.03%). Company insiders that own Keryx Biopharmaceuticals stock include Brian Adams, Greg Madison, John F Neylan and Scott A Holmes. View Institutional Ownership Trends for Keryx Biopharmaceuticals.
Who bought Keryx Biopharmaceuticals stock? Who is buying Keryx Biopharmaceuticals stock?
How do I buy Keryx Biopharmaceuticals stock?
Shares of Keryx Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Keryx Biopharmaceuticals' stock price today?
One share of Keryx Biopharmaceuticals stock can currently be purchased for approximately $7.06.
MarketBeat Community Rating for Keryx Biopharmaceuticals (NASDAQ KERX)MarketBeat's community ratings are surveys of what our community members think about Keryx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Keryx Biopharmaceuticals (NASDAQ:KERX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 6 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.40) |
| Consensus Price Target: | $8.33 (18.04% upside) |
Analysts' Ratings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/27/2017 | Maxim Group | Set Price Target | Buy | $9.00 | High |  |
| 7/25/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | $4.00 -> $7.00 | Low | |
| 7/25/2017 | Cowen and Company | Reiterated Rating | Market Perform | | Medium | |
| 1/11/2017 | Citigroup Inc. | Upgrade | Sell -> Neutral | $7.00 | N/A | |
| 11/19/2016 | FBR & Co | Reiterated Rating | Hold | | N/A | |
| 9/8/2016 | JMP Securities | Reiterated Rating | Outperform | | N/A | |
| 8/2/2016 | Raymond James Financial, Inc. | Boost Price Target | Outperform | $7.00 -> $10.00 | N/A | |
| 8/2/2016 | Ladenburg Thalmann Financial Services | Boost Price Target | Buy | $9.00 -> $10.00 | N/A | |
| 8/2/2016 | Brean Capital | Downgrade | Buy -> Hold | | N/A | |
| 8/2/2016 | Stifel Nicolaus | Downgrade | Buy -> Hold | | N/A | |
| 3/29/2016 | BTIG Research | Reiterated Rating | Sell | $2.50 | N/A | |
| 2/26/2016 | J P Morgan Chase & Co | Downgrade | Overweight -> Neutral | | N/A | |
| 8/10/2015 | Roth Capital | Downgrade | Buy -> Neutral | $11.00 -> $6.00 | N/A | |
| 8/7/2015 | MLV & Co. | Reiterated Rating | Buy | $25.00 | N/A | |
(Data available from 7/27/2015 forward)
Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)Earnings History by Quarter for Keryx Biopharmaceuticals (NASDAQ KERX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/27/2017 | Q2 2017 | ($0.17) | ($0.77) | $14.51 million | $15.10 million | View | N/A | |
| 5/4/2017 | Q1 2017 | ($0.18) | ($0.21) | $10.19 million | $11.82 million | View | Listen | |
| 3/1/2017 | Q4 2016 | ($0.25) | ($0.32) | $9.65 million | $9.53 million | View | Listen | |
| 11/9/2016 | Q316 | ($0.22) | ($0.39) | $5.53 million | $6.30 million | View | Listen | |
| 8/1/2016 | Q216 | ($0.28) | ($0.42) | $8.60 million | $9.30 million | View | Listen | |
| 4/28/2016 | Q116 | ($0.26) | ($0.39) | $6.63 million | $6.80 million | View | Listen | |
| 2/25/2016 | Q415 | ($0.25) | ($0.36) | $5.68 million | $5.80 million | View | Listen | |
| 10/29/2015 | Q3 2015 | ($0.25) | ($0.29) | $3.91 million | $4.21 million | View | Listen | |
| 8/5/2015 | Q215 | ($0.26) | ($0.26) | $2.86 million | $2.50 million | View | Listen | |
| 5/4/2015 | Q115 | ($0.30) | ($0.28) | $2.45 million | $1.20 million | View | Listen | |
| 2/27/2015 | Q414 | ($0.38) | ($0.44) | $1.70 million | $0.57 million | View | Listen | |
| 11/6/2014 | Q314 | ($0.27) | ($0.38) | $0.39 million | $0.26 million | View | Listen | |
| 8/7/2014 | Q214 | ($0.23) | ($0.24) | $0.28 million | | View | Listen | |
| 5/8/2014 | Q114 | ($0.10) | ($0.15) | $9.91 million | $10.00 million | View | Listen | |
| 3/12/2014 | Q413 | ($0.16) | ($0.21) | $2.22 million | | View | Listen | |
| 11/5/2013 | Q313 | ($0.11) | ($0.19) | $2.22 million | | View | Listen | |
| 8/1/2013 | Q2 2013 | ($0.10) | ($0.14) | | | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.01) | ($0.03) | $5.83 million | $7.00 million | View | Listen | |
| 3/12/2013 | Q4 2012 | ($0.08) | ($0.09) | | | View | Listen | |
| 11/7/2012 | Q312 | ($0.07) | ($0.08) | | | View | N/A | |
| 8/7/2012 | | ($0.09) | ($0.02) | | | View | N/A | |
| 5/8/2012 | | ($0.12) | ($0.13) | | | View | N/A | |
| 2/29/2012 | | ($0.14) | ($0.12) | | | View | N/A | |
| 8/8/2011 | | ($0.03) | ($0.05) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)Current Year EPS Consensus Estimate: $-0.69 EPS
Next Year EPS Consensus Estimate: $-0.23 EPS
Dividend History for Keryx Biopharmaceuticals (NASDAQ:KERX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Keryx Biopharmaceuticals (NASDAQ:KERX)Insider Ownership Percentage: 3.08%
Institutional Ownership Percentage: 62.26%
Insider Trades by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/24/2017 | John F. Neylan | Insider | Sell | 1,214 | $7.27 | $8,825.78 | |
| 7/5/2017 | Brian Adams | General Counsel | Sell | 641 | $7.67 | $4,916.47 | |
| 7/5/2017 | Greg Madison | Insider | Sell | 910 | $7.67 | $6,979.70 | |
| 4/28/2017 | Scott A. Holmes | CFO | Sell | 1,219 | $5.89 | $7,179.91 | |
| 4/24/2017 | John F. Neylan | Insider | Sell | 1,209 | $5.73 | $6,927.57 | |
| 4/17/2017 | Brian Adams | General Counsel | Sell | 1,090 | $5.75 | $6,267.50 | |
| 4/5/2017 | Brian Adams | General Counsel | Sell | 642 | $5.80 | $3,723.60 | |
| 4/5/2017 | Greg Madison | Insider | Sell | 911 | $5.80 | $5,283.80 | |
| 1/30/2017 | Brian Adams | General Counsel | Sell | 6,984 | $4.65 | $32,475.60 | |
| 1/30/2017 | Greg Madison | Insider | Sell | 18,248 | $4.65 | $84,853.20 | |
| 1/30/2017 | Scott A. Holmes | CFO | Sell | 8,447 | $4.65 | $39,278.55 | |
| 1/23/2017 | John F. Neylan | Insider | Sell | 1,428 | $5.39 | $7,696.92 | |
| 1/17/2017 | Brian Adams | VP | Sell | 1,265 | $6.24 | $7,893.60 | |
| 1/5/2017 | Brian Adams | VP | Sell | 759 | $6.16 | $4,675.44 | |
| 1/5/2017 | Greg Madison | Insider | Sell | 1,077 | $6.16 | $6,634.32 | |
| 10/28/2016 | Scott A. Holmes | CFO | Sell | 1,237 | $4.44 | $5,492.28 | |
| 10/24/2016 | John F. Neylan | Insider | Sell | 1,211 | $4.72 | $5,715.92 | |
| 10/17/2016 | Brian Adams | VP | Sell | 1,106 | $4.86 | $5,375.16 | |
| 10/5/2016 | Brian Adams | VP | Sell | 647 | $5.38 | $3,480.86 | |
| 10/5/2016 | Greg Madison | Insider | Sell | 917 | $5.38 | $4,933.46 | |
| 8/9/2016 | Greg Madison | Insider | Sell | 1,622 | $4.22 | $6,844.84 | |
| 7/29/2016 | Scott A. Holmes | CFO | Sell | 4,935 | $7.36 | $36,321.60 | |
| 7/25/2016 | John F. Neylan | Insider | Sell | 1,217 | $7.43 | $9,042.31 | |
| 7/15/2016 | Brian Adams | VP | Sell | 1,083 | $7.01 | $7,591.83 | |
| 7/5/2016 | Brian Adams | VP | Sell | 660 | $6.66 | $4,395.60 | |
| 7/5/2016 | Greg Madison | CEO | Sell | 936 | $6.66 | $6,233.76 | |
| 5/9/2016 | Greg Madison | CEO | Sell | 1,873 | $5.42 | $10,151.66 | |
| 4/25/2016 | John F Neylan | Insider | Sell | 4,766 | $5.21 | $24,830.86 | |
| 4/15/2016 | Brian Adams | VP | Sell | 1,060 | $5.05 | $5,353.00 | |
| 4/5/2016 | Brian Adams | VP | Sell | 759 | $4.50 | $3,415.50 | |
| 4/5/2016 | Greg Madison | CEO | Sell | 1,078 | $4.50 | $4,851.00 | |
| 2/9/2016 | Greg Madison | CEO | Sell | 1,938 | $3.23 | $6,259.74 | |
| 1/15/2016 | Brian Adams | VP | Sell | 1,322 | $3.30 | $4,362.60 | |
| 1/6/2016 | Brian Adams | VP | Sell | 3,004 | $5.16 | $15,500.64 | |
| 1/6/2016 | Greg Madison | CEO | Sell | 4,261 | $4.83 | $20,580.63 | |
| 11/4/2015 | Scott A. Holmes | CFO | Buy | 5,000 | $5.33 | $26,650.00 | |
| 10/15/2015 | Brian Adams | VP | Sell | 1,011 | $4.01 | $4,054.11 | |
| 8/21/2015 | Scott A Holmes | CFO | Buy | 5,000 | $5.72 | $28,600.00 | |
| 7/15/2015 | Brian Adams | VP | Sell | 1,086 | $9.99 | $10,849.14 | |
| 7/6/2015 | James F Oliviero III | CFO | Sell | 1,943 | $9.61 | $18,672.23 | |
| 5/6/2015 | Michael P Tarnok | Director | Buy | 10,000 | $9.73 | $97,300.00 | |
| 4/15/2015 | Brian Adams | VP | Sell | 4,320 | $12.40 | $53,568.00 | |
| 4/6/2015 | James F Oliviero III | CFO | Sell | 1,878 | $11.68 | $21,935.04 | |
| 4/6/2015 | Ron Bentsur | CEO | Sell | 1,592 | $11.68 | $18,594.56 | |
| 3/6/2015 | Greg Madison | COO | Buy | 6,380 | $12.53 | $79,941.40 | |
| 2/9/2015 | Greg Madison | COO | Sell | 6,759 | $10.95 | $74,011.05 | |
| 1/5/2015 | James F Oliviero III | CFO | Sell | 5,604 | $13.79 | $77,279.16 | |
| 1/5/2015 | Ron Bentsur | CEO | Sell | 5,574 | $13.79 | $76,865.46 | |
| 12/30/2014 | Ron Bentsur | CEO | Sell | 200,000 | $14.11 | $2,822,000.00 | |
| 12/29/2014 | Ron Bentsur | CEO | Sell | 338,977 | $13.98 | $4,738,898.46 | |
| 10/6/2014 | Ron Bentsur | CEO | Sell | 70,838 | $15.88 | $1,124,907.44 | |
| 10/3/2014 | James F Oliviero III | CFO | Sell | 2,694 | $16.14 | $43,481.16 | |
| 9/12/2014 | Ron Bentsur | CEO | Sell | 50,000 | $14.24 | $712,000.00 | |
| 9/8/2014 | James F Oliviero III | CFO | Sell | 144,237 | $15.88 | $2,290,483.56 | |
| 7/7/2014 | James F Oliviero III | CFO | Sell | 2,054 | $15.75 | $32,350.50 | |
| 7/7/2014 | Ron Bentsur | CEO | Sell | 1,788 | $15.75 | $28,161.00 | |
| 4/3/2014 | James Oliviero III | CFO | Sell | 2,087 | $16.46 | $34,352.02 | |
| 4/3/2014 | Ron Bentsur | CEO | Sell | 1,816 | $16.46 | $29,891.36 | |
| 3/21/2014 | James Oliviero III | CFO | Sell | 292,483 | $15.14 | $4,428,192.62 | |
| 1/3/2014 | James Oliviero III | CFO | Sell | 6,309 | $12.57 | $79,304.13 | |
| 1/3/2014 | Ron Bentsur | CEO | Sell | 5,257 | $12.57 | $66,080.49 | |
| 12/30/2013 | James Oliviero III | CFO | Sell | 109,500 | $12.64 | $1,384,080.00 | |
| 10/3/2013 | James Oliviero III | CFO | Sell | 1,475 | $10.25 | $15,118.75 | |
| 10/3/2013 | Ron Bentsur | CEO | Sell | 2,505 | $10.25 | $25,676.25 | |
| 7/5/2013 | James F Oliviero III | CFO | Sell | 1,438 | $7.95 | $11,432.10 | |
| 7/5/2013 | Ron Bentsur | CEO | Sell | 2,440 | $7.95 | $19,398.00 | |
| 5/13/2013 | James F Oliviero III | CFO | Sell | 29,363 | $8.34 | $244,887.42 | |
| 10/3/2012 | James F Oliviero III | CFO | Sell | 4,973 | $2.72 | $13,526.56 | |
(Data available from 1/1/2013 forward)
Headline Trends for Keryx Biopharmaceuticals (NASDAQ:KERX)
Latest Headlines for Keryx Biopharmaceuticals (NASDAQ:KERX)
| Source: |
|
| Date | Headline |
|---|
 | Keryx Biopharmaceuticals, Inc. (KERX) Earns "Equal Weight" Rating from Morgan Stanley
www.americanbankingnews.com - July 25 at 8:17 PM |
| Keryx Biopharmaceuticals, Inc. (KERX) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - July 25 at 12:12 PM |
 | What to Expect from Keryx (KERX) this Earnings Season?
finance.yahoo.com - July 22 at 5:15 AM |
| Maxim Group Reiterates "Buy" Rating for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)
www.americanbankingnews.com - July 20 at 6:32 PM |
| Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2017 Financial Results on Thursday, July 27, 2017
finance.yahoo.com - July 19 at 11:19 PM |
| ETFs with exposure to Keryx Biopharmaceuticals, Inc. : July 17, 2017
finance.yahoo.com - July 18 at 5:37 AM |
| Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 17 at 3:28 PM |
| Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - July 11 at 8:50 PM |
 | Why Keryx Biopharmaceuticals Stock Soared 11.6% Higher in June
www.fool.com - July 8 at 7:01 AM |
| ETFs with exposure to Keryx Biopharmaceuticals, Inc. : July 5, 2017
finance.yahoo.com - July 6 at 7:00 AM |
| Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Expected to Post Quarterly Sales of $14.08 Million
www.americanbankingnews.com - July 2 at 9:27 AM |
| Keryx Biopharmaceuticals, Inc. (KERX) Expected to Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - June 30 at 2:06 PM |
| Keryx Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:KERX) : June 19, 2017
finance.yahoo.com - June 19 at 5:08 PM |
| Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : June 16, 2017
finance.yahoo.com - June 16 at 7:03 PM |
| Keryx Biopharmaceuticals, Inc. (KERX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 16 at 6:32 PM |
 | Keryx's Path To Profitability Seems Clearer Now - Seeking Alpha
seekingalpha.com - June 13 at 5:55 PM |
 | Keryx Biopharmaceuticals (KERX) Up 5% Since Earnings Report: Can It Continue? - Nasdaq
www.nasdaq.com - June 9 at 11:22 PM |
| Keryx Biopharmaceuticals (KERX) Up 5% Since Earnings Report: Can It Continue?
finance.yahoo.com - June 9 at 6:21 PM |
| Brokerages Anticipate Keryx Biopharmaceuticals (KERX) Will Announce Quarterly Sales of $14.08 Million
www.americanbankingnews.com - June 8 at 11:54 AM |
| Zacks: Brokerages Anticipate Keryx Biopharmaceuticals (KERX) to Announce -$0.17 EPS
www.americanbankingnews.com - June 6 at 12:38 PM |
| Keryx Biopharmaceuticals (KERX) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - June 2 at 3:08 PM |
 | Keryx Biopharmaceuticals to Webcast its Presentation at Jefferies' 2017 Healthcare Conference on June 6, 2017 - GlobeNewswire (press release)
globenewswire.com - June 1 at 7:31 AM |
| Keryx Biopharmaceuticals to Webcast its Presentation at Jefferies’ 2017 Healthcare Conference on June 6, 2017
finance.yahoo.com - May 30 at 10:21 AM |
| Maxim Group Boosts Keryx Biopharmaceuticals (KERX) Price Target to $9.00
www.americanbankingnews.com - May 29 at 1:34 PM |
| Short Interest in Keryx Biopharmaceuticals (KERX) Declines By 20.3%
www.americanbankingnews.com - May 27 at 7:06 AM |
| Keryx Biopharmaceuticals (KERX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 22 at 6:20 PM |
| ETFs with exposure to Keryx Biopharmaceuticals, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 5:35 PM |
| Keryx Biopharmaceuticals (KERX) Expected to Post Quarterly Sales of $14.08 Million
www.americanbankingnews.com - May 12 at 1:18 PM |
| ETFs with exposure to Keryx Biopharmaceuticals, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 6:38 PM |
| Keryx Biopharmaceuticals (KERX) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - May 10 at 8:24 PM |
| Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 12:06 PM |
| Keryx Biopharmaceuticals (KERX) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 9 at 12:16 AM |
| Keryx Biopharmaceuticals (KERX) Posts Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 11:53 PM |
| Keryx Biopharmaceuticals (KERX) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 8 at 10:26 PM |
| Keryx Biopharmaceuticals (KERX) Earns "Buy" Rating from Maxim Group
www.americanbankingnews.com - May 8 at 11:43 AM |
 | Keryx Biopharma (KERX): Expanding Model And Raising PT - Maxim - StreetInsider.com
www.streetinsider.com - May 8 at 9:21 AM |
| Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat
finance.yahoo.com - May 5 at 6:07 PM |
| Edited Transcript of KERX earnings conference call or presentation 4-May-17 12:00pm GMT
finance.yahoo.com - May 5 at 6:07 PM |
| Keryx Biopharma Q1 revenues up 74%
seekingalpha.com - May 4 at 11:18 PM |
| Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results - Yahoo Finance
finance.yahoo.com - May 4 at 6:18 PM |
| Keryx Biopharma (KERX) Misses Q1 EPS by 1c, Beat on Revenues - StreetInsider.com
www.streetinsider.com - May 4 at 6:18 PM |
| Keryx Biopharmaceuticals' (KERX) CEO Greg Madison on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 4 at 6:18 PM |
| Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 6:18 PM |
| Investor Network: Keryx Biopharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 6:18 PM |
| Keryx (KERX) Posts Wider-than-Expected Q1 Loss, Sales Beat
finance.yahoo.com - May 4 at 6:18 PM |
| Keryx Biopharma reports 1Q loss
finance.yahoo.com - May 4 at 6:17 PM |
| Positive Media Coverage Very Likely to Impact Keryx Biopharmaceuticals (KERX) Share Price
www.americanbankingnews.com - May 4 at 12:48 PM |
| Keryx Biopharma (KERX) Says Auryxi is Now on Formulary at All Major Medicare Part D Plans - StreetInsider.com
www.streetinsider.com - May 3 at 8:39 PM |
| UroGen Pharma Readies $45 Million IPO
seekingalpha.com - May 2 at 10:54 AM |
| Keryx Biopharmaceuticals (KERX) Receives "Buy" Rating from Maxim Group
www.americanbankingnews.com - May 1 at 11:24 PM |
Keryx Biopharmaceuticals (KERX) Chart for Thursday, July, 27, 2017
